US FDA panel gives thumbs up to Chelsea's Northera, despite lack of data
This article was originally published in Scrip
Executive Summary
Chelsea Therapeutics on 23 February persuaded a panel of advisers to the US FDA to back Northera (droxidopa) as a therapy to improve symptoms of neurogenic orthostatic hypotension (NOH), a chronic disorder caused by a deficient release of norepinephrine, which results in a sudden drop in blood pressure when a person goes from a supine position to standing.